PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
about
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Human genetics as a model for target validation: finding new therapies for diabetes.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.Mendelian randomisation in cardiovascular research: an introduction for clinicians.Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish.Alirocumab for the treatment of hypercholesterolaemia.Bococizumab for the treatment of hypercholesterolaemia.Can LDL cholesterol be too low? Possible risks of extremely low levels.Investigational therapies for hypercholesterolemia.PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease.PCSK9 and carbohydrate metabolism: A double-edged sword.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.Exome-wide association study of plasma lipids in >300,000 individuals.The influence of big (clinical) data and genomics on precision medicine and drug development.Effects of Evolocumab on Cardiovascular Events.Leveraging Human Genetics to Understand the Relation of LDL Cholesterol with Type 2 Diabetes.Recent Developments in Mendelian Randomization Studies.Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities.Methylglyoxal attenuates insulin signaling and downregulates the enzymes involved in cholesterol biosynthesis.Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.The Role of Mitochondrial DNA (mtDNA) in the Development of Diabetic Retinopathy (DR): A Systematic Review.Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure.Electronic health records: the next wave of complex disease genetics.Unexplained reciprocal regulation of diabetes and lipoproteins.Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?Common Methods for Performing Mendelian Randomization.Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.The MR-Base platform supports systematic causal inference across the human phenome.
P2860
Q30234302-72D7B5A6-258A-4F8D-AA61-0E12A994281EQ30234612-556C62F3-F79D-41F4-B71A-A5B82C005FD7Q30234640-B65EBBF4-0B9C-458E-AD89-D38E166ECCD6Q33599961-1FC101FA-D8F6-4DA0-99D0-9A2B7280CFFFQ33623532-4A261545-C031-4ACA-8FAB-D16308231989Q33730396-B4BE573B-1D54-43CD-B9E7-560FD68056AEQ38652329-ABCA916C-AC7E-4A32-8130-69EDB7E83F2DQ38735373-493E8261-23DF-4592-BE2A-BADC312866D3Q38827776-61DB5BBE-6DFB-4439-9D8F-9A8277E84C3FQ38843982-42239B7F-1DF9-4343-83C4-6F82E4C2E4D7Q39035931-AC4C7F61-D956-46EF-B0D3-AEECEC8CBFA1Q39179689-D2AB808E-37C0-4500-8E9A-83C3A4D485A8Q39215123-36814C35-BC5F-482A-B72F-EE557042A115Q39453691-367181C3-A4C8-4369-969A-137AC72C2AB2Q40059063-743B149C-7D0F-44DD-84A5-0AFEE468E097Q42333207-4133E90F-E17A-480D-9884-985CC95CC796Q44847105-32F9B5F6-C6D4-4F56-AA60-F330CE183719Q45069779-D76A88C1-6D70-4659-A94A-22897EA56104Q45071322-CB2D0BD3-06CB-4585-8A4F-3FB2201D7B9CQ45943634-A0E3ED41-A159-41F1-A2A8-044960CEA71EQ46165468-0E93039D-0FC4-44DB-B5E9-EB31F5342C0DQ47101294-0E14695C-F425-4E71-B1CD-56C05A588F57Q47158618-04B6C89B-9BC6-45EE-8B71-086DC3F90178Q47353483-23F8D14C-3DB2-4F88-9384-90691480F5DDQ47394015-C22127A1-8CFF-4F07-B0D6-BEBDE738CA10Q47419614-FEFE6415-9135-49B6-942E-AD0E03AE7565Q47567094-B98AE0A5-69D4-4A6E-98FD-9F534807A044Q47776394-86D00A71-996C-4970-B19F-2ECE0D385FDCQ47779685-DF8CC152-CFDC-48BC-8DD6-A663EAA836D0Q48254766-CA0A0DAC-C69D-4EEA-963F-9DB9C90AA779Q49463670-88D2C706-153B-4967-AC1C-3CDBFCA45764Q49689988-88849044-9193-4C44-815E-F544E40C6CDCQ50047295-7FC8B4C8-EF84-4D8A-AC49-319E93E5479BQ52324964-95F7A7AD-F724-4A08-BE6F-1D512672C0EAQ52352782-8DE83605-C7ED-4B08-A445-1E75D83979B4Q53690107-359586B0-2F21-4D60-8969-D914D219C910Q54942141-F30D0876-6395-4FFC-BEE0-1D05E44EA1F8Q55030557-92FAA08C-8095-47DF-8EE3-84CB793F82EEQ55423842-2AA3F851-F6BD-46FD-ADBF-5FE7AE628ADAQ55427190-642BCEFB-23E9-4AB2-ACA7-517015C1DC78
P2860
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
@en
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
@nl
type
label
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
@en
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
@nl
prefLabel
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
@en
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
@nl
P2093
P2860
P50
P1476
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
@en
P2093
Abdonas Tamosiunas
Adelaida Sanchez-Galvez
Alex P Reiner
Andre Uitterlinden
Andrew Nicolaides
Andrie G Panayiotou
Andrzej Pająk
Anke H Maitland-van der Zee
Archie Campbell
Bernardo Lessa Horta
P2860
P304
P356
10.1016/S2213-8587(16)30396-5
P407
P50
P577
2016-11-28T00:00:00Z